echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > The FDA revoked the emergency use authorization for the treatment of COVID-19 with chloroquine and hydroxychloroquine

    The FDA revoked the emergency use authorization for the treatment of COVID-19 with chloroquine and hydroxychloroquine

    • Last Update: 2021-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    , the U.S. Food and Drug Administration (FDA) issued a statement revoking the Emergency Use Authorization (EUA) for the treatment of COVID-19 hospitalized patients. On March 28, the FDA issued the emergency authorization.In its latest statement, the FDA said it determined that chloroquine and hydroxychloroquine may not be effective in treating COVID-19.This is based on the latest results from a large randomized clinical trial of hospitalized patients (similar to those authorized to use chloroquine and hydroxychloroquine). The results showed that hydroxychloroquine had no benefit in mortality or accelerated recovery. The results are consistent with other new data: chloroquine and hydroxychloroquine dosing programmes are unlikely to kill or suppress the viruses that cause COVID-19. All the scientific evidence available today suggests a lack of benefits.In addition, given persistent severe heart events and other potentially serious side effects, the potential benefits of chloroquine and hydroxychloroquine do not exceed the known and potential risks of authorized use."While other clinical trials continue to evaluate the potential benefits of these drugs in treating or preventing COVID-19, we determine that emergency use authorization is no longer appropriate," said Dr. Patrizia Cavazzoni, acting director of the FDA's Center for Drug Evaluation. We took this action after a rigorous assessment by scientists at our drug evaluation and research center. " (Biological exploration)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.